DPP4 and prostate carcinoma: Moreover, our results showing the capability of ARV p17 to block FGF-2-induced angiogenesis through the involvement of DPP4 are in line with the previous studies showing the ability of DPP4 to inhibit the malignant phenotype of prostate cancer cells by blocking FGF-2 signaling [58].